Drug Profile
Cetuximab biosimilar - Outlook Therapeutics
Alternative Names: ONS-1055Latest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator Oncobiologics
- Developer Outlook Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Colorectal cancer; Head and neck cancer
Highest Development Phases
- No development reported Colorectal cancer; Head and neck cancer
Most Recent Events
- 03 Dec 2018 Oncobiologics is now called Outlook Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (IV, Infusion)